EQT Private Equity Plans €10.8 Billion All-Cash Acquisition of QIAGEN

EQT Private Equity has announced an agreement to acquire QIAGEN N.V., a molecular testing technology provider, in an all-cash public takeover valued at approximately €10.8 billion. The offer of €46.50 per share represents a 40.3% premium for QIAGEN shareholders. Both QIAGEN's Supervisory and Managing Boards have unanimously recommended the transaction, which is expected to close in mid-2027, pending a minimum acceptance threshold and regulatory approvals.